×
About 2,727 results

ALLMedicine™ Pituitary Tumors Center

Research & Reviews  1,321 results

DNA Methylation-based Signatures Classify Sporadic Pituitary Tumors According to Clinic...
https://doi.org/10.1093/neuonc/noab044
Neuro-oncology Mosella MS, Sabedot TS et. al.

Feb 25th, 2021 - Distinct genome-wide methylation patterns cluster pituitary neuroendocrine tumors (PitNETs) into molecular groups associated with specific clinicopathological features. Here we aim to identify, characterize and validate methylation signatures that...

SOX2 is required independently in both stem and differentiated cells for pituitary tumo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896314
Proceedings of the National Academy of Sciences of the Un... Moncho-Amor V, Chakravarty P et. al.

Feb 12th, 2021 - P27, a cell cycle inhibitor, is also able to drive repression of Sox2 This interaction plays a crucial role during development of p27 -/- pituitary tumors because loss of one copy of Sox2 impairs tumorigenesis [H. Li et al., Cell Stem Cell 11, 845...

Pituitary tumors: genetic and molecular factors underlying pathogenesis and clinical be...
https://doi.org/10.1159/000514862
Neuroendocrinology Spada A, Mantovani G et. al.

Feb 1st, 2021 - Pituitary neuroendocrine tumors (PitNETs) are the most common intracranial neoplasms. Although generally benign, they can show a clinically aggressive course, with local invasion, recurrences and resistance to medical treatment. No universally acc...

A survey of surgically resected pituitary incidentalomas and a comparison of the clinic...
https://doi.org/10.1507/endocrj.EJ20-0335
Endocrine Journal; Ono M, Fukuda I et. al.

Jan 28th, 2021 - Pituitary tumors are discovered either incidentally by imaging studies (incidentalomas) or via evaluation of certain clinical symptoms (symptomatic tumors). In this study, we first surveyed patients with incidentalomas who underwent surgery. Cases...

Immune profiling of pituitary tumors reveals variations in immune infiltration and chec...
https://doi.org/10.1007/s11102-020-01114-3 10.1093/neuonc/noz150 10.1007/s12022-017-9498-z 10.1007/s00401-017-1769-8 10.1001/jama.2016.19699 10.1530/EJE-17-0796 10.1530/EJE-16-0979 10.1084/jem.192.7.1027 10.1056/NEJMoa1801005 10.1056/NEJMoa1712126 10.1056/NEJMoa1003466 10.1038/nrclinonc.2017.88 10.1016/j.cell.2017.01.017 10.1038/nrc3239 10.1186/s12943-019-1091-2 10.1038/s41423-018-0086-z 10.1038/85330 10.1158/1078-0432.CCR-16-1761 10.1084/jem.20100619 10.1158/0008-5472.CAN-13-1504 10.4049/jimmunol.1100660 10.1172/JCI74589 10.1084/jem.171.5.1393 10.1084/jem.176.2.327 10.1038/s41590-018-0257-1 10.1038/s41590-018-0217-9 10.1016/0161-5890(87)90122-2 10.1111/j.1600-065X.2009.00766.x 10.1084/jem.20071341 10.4049/jimmunol.172.8.4821 10.3390/jcm8081107 10.1210/jc.2018-01347 10.3390/cancers11101605 10.1210/jc.2009-1583 10.1507/endocrj.45.357 10.1177/030089169007600605 10.1007/s12022-015-9383-6 10.1038/s41388-019-0779-5 10.3390/jcm8050695 10.18632/oncotarget.12088 10.1007/s11060-018-2844-2 10.1097/MD.0000000000009056 10.1158/1078-0432.CCR-18-3486 10.1097/PAS.0b013e31827e50fa 10.1038/modpathol.2013.230 10.1097/pai.0000000000000207 10.1038/bjc.2015.284 10.1007/s00262-014-1651-7 10.18632/oncotarget.3082 10.1186/s40478-016-0394-4 10.3389/fendo.2019.00745 10.1074/jbc.M113.477950 10.3390/cancers6010376 10.1038/nrc2734 10.1002/stem.1752 10.1002/hep.27968 10.21037/hbsn.2016.03.02 10.1016/j.coi.2008.03.010 10.4049/jimmunol.179.4.2170 10.1186/s40478-019-0830-3 10.1186/s13045-019-0738-1 10.18632/oncotarget.26775 10.1126/science.1224922 10.1158/1078-0432.CCR-16-0790 10.1210/en.2016-1967 10.1126/science.aaf8399 10.1016/j.ccell.2018.03.007 10.1101/gr.212225.116 10.1038/s41598-019-49878-4 10.1056/NEJMoa1500596 10.1136/jim-2016-000342 10.1007/s00535-019-01620-7 10.18632/oncotarget.23790 10.1634/theoncologist.2016-0046 10.1210/jc.2017-01401 10.1016/j.cell.2011.02.013 10.1155/2014/989574 10.1155/2014/608497 10.1080/08820530902805651 10.1158/0008-5472.CAN-09-0167 10.1158/0008-5472.CAN-11-0241 10.1002/glia.20414 10.1387/ijdb.103225yz
Pituitary Mei Y, Bi WL et. al.

Jan 25th, 2021 - Pituitary tumors are the second most common primary brain tumors. Functional tumors demonstrate increased PD-L1 expression, but expression of other checkpoint regulators has not been characterized. We sought to characterize the immune microenviron...

see more →

Guidelines  3 results

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on th...
https://doi.org/10.1227/NEU.0000000000001386
Neurosurgery Aghi MK, Chen CC et. al.

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. To create evidence-based guidelines for the initial management of NFPAs. A multidisciplinary task force composed of physician volunteers and evidence-based medicine-...

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Pre...
https://doi.org/10.1227/NEU.0000000000001388
Neurosurgery Newman SA, Turbin RE et. al.

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. Visual symptoms from NFPAs are common and include visual field defects, loss of central vision, and motility problems resulting in diplopia. To create evidence-based...

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Pos...
https://doi.org/10.1227/NEU.0000000000001392
Neurosurgery Ziu M, Dunn IF et. al.

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. Due to the lack of hormonal hypersecretion, posttreatment follow-up evaluation of NFPAs is challenging. To create evidence-based guidelines in an attempt to formulat...

see more →

Clinicaltrials.gov  1,363 results

DNA Methylation-based Signatures Classify Sporadic Pituitary Tumors According to Clinic...
https://doi.org/10.1093/neuonc/noab044
Neuro-oncology Mosella MS, Sabedot TS et. al.

Feb 25th, 2021 - Distinct genome-wide methylation patterns cluster pituitary neuroendocrine tumors (PitNETs) into molecular groups associated with specific clinicopathological features. Here we aim to identify, characterize and validate methylation signatures that...

SOX2 is required independently in both stem and differentiated cells for pituitary tumo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896314
Proceedings of the National Academy of Sciences of the Un... Moncho-Amor V, Chakravarty P et. al.

Feb 12th, 2021 - P27, a cell cycle inhibitor, is also able to drive repression of Sox2 This interaction plays a crucial role during development of p27 -/- pituitary tumors because loss of one copy of Sox2 impairs tumorigenesis [H. Li et al., Cell Stem Cell 11, 845...

Pituitary tumors: genetic and molecular factors underlying pathogenesis and clinical be...
https://doi.org/10.1159/000514862
Neuroendocrinology Spada A, Mantovani G et. al.

Feb 1st, 2021 - Pituitary neuroendocrine tumors (PitNETs) are the most common intracranial neoplasms. Although generally benign, they can show a clinically aggressive course, with local invasion, recurrences and resistance to medical treatment. No universally acc...

A survey of surgically resected pituitary incidentalomas and a comparison of the clinic...
https://doi.org/10.1507/endocrj.EJ20-0335
Endocrine Journal; Ono M, Fukuda I et. al.

Jan 28th, 2021 - Pituitary tumors are discovered either incidentally by imaging studies (incidentalomas) or via evaluation of certain clinical symptoms (symptomatic tumors). In this study, we first surveyed patients with incidentalomas who underwent surgery. Cases...

Immune profiling of pituitary tumors reveals variations in immune infiltration and chec...
https://doi.org/10.1007/s11102-020-01114-3 10.1093/neuonc/noz150 10.1007/s12022-017-9498-z 10.1007/s00401-017-1769-8 10.1001/jama.2016.19699 10.1530/EJE-17-0796 10.1530/EJE-16-0979 10.1084/jem.192.7.1027 10.1056/NEJMoa1801005 10.1056/NEJMoa1712126 10.1056/NEJMoa1003466 10.1038/nrclinonc.2017.88 10.1016/j.cell.2017.01.017 10.1038/nrc3239 10.1186/s12943-019-1091-2 10.1038/s41423-018-0086-z 10.1038/85330 10.1158/1078-0432.CCR-16-1761 10.1084/jem.20100619 10.1158/0008-5472.CAN-13-1504 10.4049/jimmunol.1100660 10.1172/JCI74589 10.1084/jem.171.5.1393 10.1084/jem.176.2.327 10.1038/s41590-018-0257-1 10.1038/s41590-018-0217-9 10.1016/0161-5890(87)90122-2 10.1111/j.1600-065X.2009.00766.x 10.1084/jem.20071341 10.4049/jimmunol.172.8.4821 10.3390/jcm8081107 10.1210/jc.2018-01347 10.3390/cancers11101605 10.1210/jc.2009-1583 10.1507/endocrj.45.357 10.1177/030089169007600605 10.1007/s12022-015-9383-6 10.1038/s41388-019-0779-5 10.3390/jcm8050695 10.18632/oncotarget.12088 10.1007/s11060-018-2844-2 10.1097/MD.0000000000009056 10.1158/1078-0432.CCR-18-3486 10.1097/PAS.0b013e31827e50fa 10.1038/modpathol.2013.230 10.1097/pai.0000000000000207 10.1038/bjc.2015.284 10.1007/s00262-014-1651-7 10.18632/oncotarget.3082 10.1186/s40478-016-0394-4 10.3389/fendo.2019.00745 10.1074/jbc.M113.477950 10.3390/cancers6010376 10.1038/nrc2734 10.1002/stem.1752 10.1002/hep.27968 10.21037/hbsn.2016.03.02 10.1016/j.coi.2008.03.010 10.4049/jimmunol.179.4.2170 10.1186/s40478-019-0830-3 10.1186/s13045-019-0738-1 10.18632/oncotarget.26775 10.1126/science.1224922 10.1158/1078-0432.CCR-16-0790 10.1210/en.2016-1967 10.1126/science.aaf8399 10.1016/j.ccell.2018.03.007 10.1101/gr.212225.116 10.1038/s41598-019-49878-4 10.1056/NEJMoa1500596 10.1136/jim-2016-000342 10.1007/s00535-019-01620-7 10.18632/oncotarget.23790 10.1634/theoncologist.2016-0046 10.1210/jc.2017-01401 10.1016/j.cell.2011.02.013 10.1155/2014/989574 10.1155/2014/608497 10.1080/08820530902805651 10.1158/0008-5472.CAN-09-0167 10.1158/0008-5472.CAN-11-0241 10.1002/glia.20414 10.1387/ijdb.103225yz
Pituitary Mei Y, Bi WL et. al.

Jan 25th, 2021 - Pituitary tumors are the second most common primary brain tumors. Functional tumors demonstrate increased PD-L1 expression, but expression of other checkpoint regulators has not been characterized. We sought to characterize the immune microenviron...

see more →

News  23 results

New Clinical Practice Guidelines, November 2017
https://reference.medscape.com/viewarticle/888107_10

Nov 7th, 2017 - Pituitary Tumors and Carcinomas European Society of Endocrinology Recommend all pituitary tumors undergo histopathologic analysis, which should include, at a minimum, immunodetection of pituitary hormones and Ki-67 proliferative index evaluation. ...

Temozolomide may help half of patients with aggressive pituitary tumors
https://www.mdedge.com/familymedicine/article/134819/endocrine-cancer/temozolomide-may-help-half-patients-aggressive
Clinical Endocrinology News; Michele G. Sullivan

Apr 2nd, 2017 - ORLANDO – Temozolomide, an alkylating agent approved for glioblastoma, improved long-term survival in about half of patients who took it for aggressive pituitary tumors, a retrospective study has determined. The study, conducted by members of the.

What Do You Consider to Be the Top Medical Advances of the Past 20 Years?
https://reference.medscape.com/viewarticle/845121_8

May 26th, 2015 - Which of the following would you say has been the biggest advance in endocrinology over the past 20 years? Your Peers Chose: The discovery of leptin 0% Introduction of tyrosine kinase inhibitors (TKIs) in the management of advanced thyroid cancers...

March 2015 Quiz 1
https://www.mdedge.com/gihepnews/article/97317/march-2015-quiz-1

Feb 20th, 2015 - ANSWER: D Critique The patient is most likely to have Zollinger-Ellison syndrome (ZES), a condition caused by a gastrinoma. In 25% of cases, ZES is associated with multiple endocrine neoplasia type 1 (MEN-1).

Pegvisomant Looks Safe for Long-Term Acromegaly Treatment
https://www.mdedge.com/internalmedicine/article/48806/endocrinology/pegvisomant-looks-safe-long-term-acromegaly-treatment
Jennie Smith

Mar 6th, 2012 - Interim results from an ongoing, registry-based phase IV surveillance study show that the medication pegvisomant is safe and effective in treating acromegaly, a disorder caused by pituitary tumors. Among 1,288 people treated for acromegaly with pe.

see more →

Patient Education  17 results see all →